Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $17.7 million.

  • Tg Therapeutics' Share-based Compensation rose 4988.14% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.0 million, marking a year-over-year increase of 5249.35%. This contributed to the annual value of $42.5 million for FY2024, which is 1214.77% up from last year.
  • As of Q3 2025, Tg Therapeutics' Share-based Compensation stood at $17.7 million, which was up 4988.14% from $16.4 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Share-based Compensation registered a high of $36.5 million during Q4 2022, and its lowest value of -$1.0 million during Q2 2022.
  • Over the past 5 years, Tg Therapeutics' median Share-based Compensation value was $11.9 million (recorded in 2024), while the average stood at $12.4 million.
  • Per our database at Business Quant, Tg Therapeutics' Share-based Compensation crashed by 10613.5% in 2022 and then soared by 135000.0% in 2023.
  • Tg Therapeutics' Share-based Compensation (Quarter) stood at $14.4 million in 2021, then soared by 153.98% to $36.5 million in 2022, then plummeted by 74.31% to $9.4 million in 2023, then rose by 27.31% to $11.9 million in 2024, then soared by 48.02% to $17.7 million in 2025.
  • Its last three reported values are $17.7 million in Q3 2025, $16.4 million for Q2 2025, and $15.0 million during Q1 2025.